ClinicalTrials.gg
RecruitingNCT05008809Updated Dec 12, 2025

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

A Phase 3 interventional study of mFOLFOX6 and mFOLFOXIRI in Colorectal Cancer, sponsored by Dominik Paul Modest. Recruiting at 79 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Dominik Paul Modest · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Colorectal Neoplasms with a site in Germany — 63 open to participants now, 90 under way, 19 of them phase 3. Colorectal Neoplasms · Germany.

Planned enrollment
71st of 290
507 · median 169
Started
2021
with 20 others
Phase 3
74 of 353
11 open now
Primary completion
2027-11
later than 50 of 89 live
Registered
272nd of 353
by date

Among the 353 studies in Colorectal Neoplasms with a site in Germany, this one is the 71st largest by planned enrollment of the 290 interventional ones that give a count, is one of 21 that started in 2021, is one of 74 in phase 3, reaches primary completion later than 50 of the 89 other live ones, and was the 272nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

63 of the 353 studies in Colorectal Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Colorectal Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with metastatic colorectal cancer after definite interventional therapy of all lesions are randomized in a 2:1 fashion (favoring active therapy) to investigate the efficacy, patient reported quality of life and safety of mFOLFOXIRI/mFOLFOX-6 as additive treatment (Arm A) versus active follow-up/surveillance (Arm B).

Read the detailed description

The trial will consist of both a clinical and translational part. During the study, re-assessments (radiologic assessment, blood and QoL) will be conducted for all trial subject of the trial every 3 months. Tumor biopsies will be collected at screening (baseline sample) and in case of relapse of disease if a new tumor sample is obtained.

The objective of the re-assessments is detection of relapse either radiologically or within the translational material (blood samples with ctDNA dynamics and tumor - if available from relapses). CT scans of thorax/abdomen and/or MRI scans will be performed every 3 months within the 2 years after randomization. After the first two relapse-free years, intervals should be stretched to 6 months in the third and following years after study start. Structured follow-up for up to 60 months after randomization should be maintained for both arms.

Patients in Arm A receive additive study drug intervention (mFOLFOXIRI or mFOLFOX-6) for up to six months (12 cycles) after randomization with additional clinical and safety assessments.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient's signed .
  2. Patient's age ≥18 years at the time of signing the informed consent.
  3. confirmed adenocarcinoma of the colon or rectum.
  4. Resected (R0 or R1) and/or effectively treated (all techniques allowed) of colorectal cancer within 3-10 weeks before randomization (earlier randomisation allowed if at least 3 weeks interval between intervention and treatment start is guaranteed) AND resected primary tumor (synchronous or metachronous). In cases of synchronous metastases the interval of 3-10 weeks might be calculated following the removal of the primary tumor if this intervention was the last to address all tumor lesions.
  5. Absence of significant active wound healing complications (if applicable) at randomization. Resolved wound healing complications after resection/ablation are acceptable for inclusion into the trial.
  6. No radiographic evidence of active metastatic disease at study entry in a CT and/or MRI scan not older than 10 weeks prior randomization. Pre-surgery/ablation images are eligible for the study if all lesions have been addressed in the interval.
  7. performance status 0-2.
  8. Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results:

    • >= 1.5 x 109/L (1500/µL)
    • ≥ 80 g/L (8 g/dL)
    • count ≥ 100 x109/L (100000/µL) without transfusion
    • Total serum of ≤ 1.5 x (ULN)
    • (AST/GOT) ≤ 3.0 × ULN.
    • Calculated (GFR) according to formula or according to MDRD ≥ 50 mL/min or serum creatinine ≤ 1.5 x ULN
  9. Patients without anticoagulation need to present with an \< 1.5 x ULN and PTT \< 1.5 x ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial.
  10. Proficient fluorouracil metabolism as defined:

    1. Prior treatment with 5-FU or capecitabine without unusual toxicity or
    2. If tested, normal DPD deficiency test according to the standard of the study site or
    3. If tested, in patients with DPD deficiency test with a CPIC activity score of 1.0-1.5 fluoropyrimidine/capecitabine dosage should be reduced by 50%
  11. For women of (WOCBP): negative pregnancy test within 14 days before randomization and agreement to remain abstinent (refrain from heterosexual intercourse) or use methods with a failure rate of \< 1% per year during the treatment period and for at least 9 months after the last dose of Oxaliplatin or for at least 6 months after the last dose of all other study treatment.

A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male partner's sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

For men: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period.

Exclusion criteria

Exclusion Criteria:

  1. Treatment of greater than 3 cm with radio-frequency/microwave ablation within 24 months prior to study entry if applicable.
  2. Treatment of metastases greater than 5 cm with radiation (stereotactic/ brachytherapy) within 24 months prior to study entry if applicable.
  3. Any previous systemic therapy is allowed for inclusion into the trial. However, if previous oxaliplatin-containing chemotherapy at any time for metastatic or localized disease was carried out, the inclusion into the trial is permitted under the condition, that

    1. A total duration of oxaliplatin-based therapy of six months (i.e. 12 cycles of FOLFOX / FOLFOXIRI or 8 cycles CAPOX) is not exceeded - including therapy within the FIRE-9/PORT trial
    2. If already more than three months of oxaliplatin-based therapy (i.e. >6 cycles of FOLFOX / FOLFOXIRI or >4 cycles CAPOX) was used, the study therapy should be started with an irinotecan-based regimen (i.e. FOLFIRI or FOLFOXIRI) However, in the case of FOLFOXIRI therapy in the trial, the above mention regulation concerning the total dosing of oxaliplatin still applies (i.e. 12 cycles of FOLFOX / FOLFOXIRI or 8 cycles CAPOX should not be exceeded - including therapy within the FIRE-9/PORT trial).
  4. Class III or greater heart failure by clinical judgement.
  5. Myocardial infarction within 6 months prior to randomization; percutaneous transluminal coronary angioplasty (PTCA) with or without stenting within 6 months prior to randomization.
  6. Unstable angina pectoris.
  7. Unstable cardiac arrhythmia > grade 2 despite anti-arrhythmic therapy.
  8. Ongoing toxicities > grade 2 NCI CTCAE
  9. Active uncontrolled infection by investigator's perspective.
  10. Severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture.
  11. Known to 5-FU, folinic acid, irinotecan, oxaliplatin or capecitabine or to any of the other listed in section 6.1 of the corresponding SmPC.
  12. Recent or concomitant treatment with brivudine.
  13. Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE version 5.0 (see appendix 2)).
  14. Inflammatory bowel disease and/or bowel obstruction.
  15. Simultaneous application of Johannis herbs preparations.
  16. Pernicious or other megaloblastic anemia caused by vitamin B12 deficiency.
  17. Major surgical procedure, open , or significant traumatic injury within 21 days prior to randomization or at least to intended treatment start, or anticipation of need for major surgical procedure during the course of the study or non-recovery from side effects of any such procedure.
  18. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
  19. Medical history of malignant disease other than mCRC with the following exceptions:

    • patients who have been disease-free for at least three years before randomization
    • patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer
    • patients with any treated or untreated malignant disease that is associated with a 5-year survival prognosis of ≥ 90% and does not require active therapy
  20. Known alcohol or drug abuse.
  21. Pregnant or breastfeeding females.
  22. Participation in a clinical trial or experimental drug treatment within 28 days prior to potential inclusion in the clinical trial or within a period of 5 half-lives of the substances administered in a clinical trial or during an experimental drug treatment prior to potential inclusion in the clinical trial, depending on which period is longest, or simultaneous participation in another clinical trial while taking part in this clinical trial.
  23. Patients depending on Sponsor, investigator or study site.
  24. Suspected SARS-CoV-2 infection with or without symptoms (evaluation according to local policy in respective center with respect to actual status of pandemic and with reference to the policy that would apply to patients with similar therapy outside the trial). This may include assessment of vaccination status, anamnesis, physical examination and potentially antigen and/or PCR testing.
  25. Patient committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  26. Limited legal capacity.
  27. Concomitant administration of strong and/or UGT1A1 inducers (e.g. Rifampicin, Carbamazepin, Phenobarbital, Phenytoin or Apalutamid).
  28. Planned inoculation/vaccination with a during treatment with Oxaliplatin and/or Irinotecan, and until 6 months after treatment with Irinotecan.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
507 participants (estimated)

Study arms

  • Experimental
    Treatment

    Active treatment with mFOLFOXIRI or mFOLFOX6 or FOLFIRI q2w or CAPOX q3w up to six months followed by structured Follow-up for up to five years after randomization

    Drug: mFOLFOX6 · Drug: mFOLFOXIRI · Drug: FOLFIRI · Drug: CAPOX

  • No intervention
    Control

    Structured Follow-up for up to five years after randomization

Interventions

  • DrugmFOLFOX6

    Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.

    Also known as: Folinic acid, Oxaliplatin, 5-fluorouracil (FU)

  • DrugmFOLFOXIRI

    Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.

    Also known as: Folinic acid, Oxaliplatin, 5-FU, Irinotecan

  • DrugFOLFIRI

    Folinic acid: 400mg/m², 1-2h IV Infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Irinotecan: 180 mg/m², 90-120 min IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles is administered.

    Also known as: Folinic acid, 5-FU

  • DrugCAPOX

    Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.

    Also known as: Capecitaine, Oxaliplatin

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) time

    time from randomization to death or evidence of disease relapse/progression (whatever occurs first)

    Time frame: 24 months

Secondary outcomes

  1. Overall survival (OS)

    time from randomization to the date of death of any cause

    Time frame: at least 5 years after randomization

  2. Control ol lesions

    Local or distant control of lesions according to ablative technique (surgery vs. ablation vs. radiation)

    Time frame: up to 5 years after randomization

  3. (Serious) Adverse Events

    Type, incidence, severity, and causal relationship to active chemotherapy of non-serious adverse events and serious adverse events (severity evaluated according to CTCAE version 5.0)

    Time frame: up to 2 years after randomization

  4. Quality of life (QoL)

    Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L

    Time frame: up to 5 years after randomization

07

Study locations

72 of 79 sites recruiting
  • Klinikum St. Marien Amberg
    Amberg, Germany
    Recruiting
    • Ludwig Fischer von Weikersthal, Dr. · Contact
  • Helios Klinikum Bad Saarow
    Bad Saarow, Germany
    Recruiting
    • Daniel Pink, Dr. · Contact
  • Klinikum Bayreuth
    Bayreuth, Germany
    Recruiting
    • Alexander Kiani, Prof. Dr. · Contact
  • Charité Universitätsmedizin Berlin
    Berlin, 13353, Germany
    Recruiting
  • Helios Klinikum Emil von Behring
    Berlin, Germany
    Recruiting
    • Börge Arndt, Dr. · Contact
  • MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim
    Berlin, Germany
    Recruiting
    • Markus Schuler, Dr. · Contact
  • Vivantes Klinikum am Urban Berlin
    Berlin, Germany
    Recruiting
    • Annette Dieing, Dr. · Contact
  • Vivantes Klinikum Spandau Berlin
    Berlin, Germany
    Recruiting
    • Jörg-Christian Rath, Dr. · Contact
  • St. Josef-Hospital Bochum
    Bochum, Germany
    Recruiting
    • Anke Reinacher-Schick, Prof. Dr. · Contact
  • Johanniterkrankenhaus Bonn
    Bonn, Germany
    Recruiting
    • Yon-Dschun Ko, Prof. Dr. · Contact
  • Diakonie-Krankenhaus Bremen
    Bremen, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Klinikum Chemnitz
    Chemnitz, Germany
    Recruiting
    • Jack Chater, Dr. · Contact
  • Kliniken der Satdt Köln
    Cologne, Germany
    Recruiting
    • Bernhard Sibbing, Dr. · Contact
  • Klinikum Darmstadt
    Darmstadt, Germany
    Recruiting
    • Carl Schimanski, Prof. Dr. · Contact
  • DONAUISAR Klinikum Deggendorf
    Deggendorf, Germany
    Recruiting
    • Christian Spoer, Dr. · Contact
  • Städtisches Klinikum Dessau
    Dessau, Germany
    Recruiting
    • Gerhard Behre, Prof. Dr. · Contact
  • Onkologische-Gemeinschaftspraxis Dresden
    Dresden, Germany
    Recruiting
    • Lutz Jacobasch, Dr. · Contact
  • Onkozentrum Dresden
    Dresden, Germany
    Recruiting
    • Steffen Dörfel · Contact
  • Universitätsklinikum Düsseldorf
    Düsseldorf, Germany
    Recruiting
    • Christoph Roderburg, Prof. Dr. · Contact
  • Kliniken Essen-Mitte
    Essen, Germany
    Recruiting
    • Christian Müller, Dr. · Contact
  • Universitätsklinikum Essen
    Essen, Germany
    Recruiting
    • Stefan Kasper-Virchow, Prof. Dr. · Contact
  • KHNW Frankfurt
    Frankfurt, Germany
    Recruiting
    • Thorsten Götze, PD Dr. · Contact
  • Markus-Krankenhaus Frankfurt
    Frankfurt, Germany
    Recruiting
    • Silvan Becker, Dr. · Contact
  • Universitätsklinikum Frankfurt
    Frankfurt, Germany
    Recruiting
    • Christine Koch, Dr. · Contact
  • Universitätsklinikum Freiburg
    Freiburg im Breisgau, Germany
    Recruiting
    • Michael Quante, Prof. Dr. · Contact
  • Gemeinschaftspraxis internistische Onkologie Fürth
    Fürth, Germany
    Recruiting
    • Jochen Wilke, Dr. · Contact
  • Niels-Stensen Kliniken Georgsmarienhütte
    Georgsmarienhütte, Germany
    Recruiting
    • Jens Atzpodien, Prof. Dr. · Contact
  • Praxis Hämatologie Onkologie Gießen
    Giessen, Germany
    Recruiting
    • Georg Schließer, Dr. · Contact
  • Universitätsmedizin Göttingen
    Göttingen, Germany
    Recruiting
    • Yong-Jun Peter Jo, Dr. · Contact
  • Universitätsklinikum Halle
    Halle, Germany
    Recruiting
    • Mascha Binder, Prof. Dr. · Contact
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, Germany
    Recruiting
    • Marianne Sinn, PD Dr. · Contact
  • Medizinische Hochschule Hannover
    Hanover, Germany
    Recruiting
    • Arndt Vogel, Prof. Dr. · Contact
  • St. Anna Hospital Herne
    Herne, Germany
    Recruiting
    • Vera Heuer, Dr. · Contact
  • Universitätsklinikum des Saarlandes
    Homburg, Germany
    Recruiting
    • Matthias Glanemann, Prof. Dr. · Contact
  • Klinikum Ingolstadt GmbH
    Ingolstadt, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Jena
    Jena, Germany
    Recruiting
    • Udo Lindig, Dr. · Contact
  • Klinikum Landshut
    Landshut, Germany
    Recruiting
    • Christian Bogner, Dr. · Contact
  • VK&K Studien Landshut
    Landshut, Germany
    Recruiting
    • Florian Kaiser, Dr. · Contact
  • Studienzentrum UnterEms Leer
    Leer, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Leipzig
    Leipzig, Germany
    Recruiting
    • Ulrich Hacker, Prof. Dr. · Contact
  • Klinikum Leverkusen
    Leverkusen, Germany
    Recruiting
    • Andrea Heider, Dr. · Contact
  • Klinikum Lippe
    Lippe, Germany
    Recruiting
    • Christian Constantin, Dr. · Contact
  • Klinikum Ludwigsburg
    Ludwigsburg, Germany
    Recruiting
    • Stefan Angermeier, Dr. · Contact
  • Klinikum Magdeburg
    Magdeburg, Germany
    Recruiting
    • Christoph Kahl, Prof. Dr. · Contact
  • Universitätsmedizin Mainz
    Mainz, Germany
    Recruiting
    • Markus Möhler, Prof. Dr. · Contact
  • OnkoNet Marburg GmbH
    Marburg, Germany
    Recruiting
    • Christina Balser, Dr. · Contact
  • Philipps-Universität Marburg
    Marburg, Germany
    Recruiting
    • Jorge Riera, Dr. · Contact
  • Johannes Wesling Klinikum Minden
    Minden, Germany
    Recruiting
    • Hans-Joachim Tischler, Dr. · Contact
  • Kliniken Maria Hilf Mönchengladbach
    Mönchengladbach, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Klinikum der Universität München
    München, Germany
    Recruiting
    • Victoria Probst, Dr. · Contact
  • Klinikum rechts der Isar TU München
    München, Germany
    Recruiting
    • Sylvie Lorenzen, Prof. Dr. · Contact
  • München Klinik Bogenhausen
    München, Germany
    Recruiting
    • Martin Fuchs, Dr. · Contact
  • München Klinik Neuperlach
    München, Germany
    Recruiting
    • Meinolf Karthaus, Prof. Dr. · Contact
  • Gemeinschaftspraxis Münster
    Münster, Germany
    Recruiting
    • Christian Lerchenmüller, Dr. · Contact
  • Universitätsklinikum Münster
    Münster, Germany
    Recruiting
    • Klaus Wethmar, Dr. Dr. · Contact
  • Friedrich-Ebert-Krankenhaus Neumünster
    Neumünster, Germany
    Recruiting
    • Siegfried Haas, Dr. · Contact
  • Lukaskrankenhaus Neuss
    Neuss, Germany
    Recruiting
    • Ulf Reinhart, Dr. · Contact
  • Klinikum Nürnberg
    Nuremberg, Germany
    Recruiting
    • Gabriele Siegler, Dr. · Contact
  • Pi.Tri-Studien GmbH Offenburg
    Offenburg, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Klinikum Passau
    Passau, Germany
    Recruiting
    • Thomas Südhoff, Prof. Dr. · Contact
  • Schwerpunktpraxis Penzberg
    Penzberg, Germany
    Recruiting
    • Michael Sandherr, PD Dr. · Contact
  • Ernst von Bergmann Klinikum Potsdam
    Potsdam, Germany
    Recruiting
    • Matthias Paland, Dr. · Contact
  • Studienzentrum Onkologie Ravensburg
    Ravensburg, Germany
    Recruiting
    • Tobias Dechow, Prof. Dr. · Contact
  • Krankenhaus Barmherzige Brüder Regensburg
    Regensburg, Germany
    Recruiting
    • Anke Schlenska-Lange, Dr. · Contact
  • Universitätsklinikum Regensburg
    Regensburg, Germany
    Recruiting
    • Hans Jürgen Schlitt, Prof. Dr. · Contact
  • Kreiskliniken Reutlingen
    Reutlingen, Germany
    Recruiting
    • Stefan Kubicka, Prof. Dr. · Contact
  • Mathias Spital Rheine
    Rheine, Germany
    Recruiting
    • Sebastian Bröckling, Dr. · Contact
  • RoMed Klinikum Rosenheim
    Rosenheim, Germany
    Recruiting
    • Gerhard Gerhard Puchtler, Dr. · Contact
  • Universitätsmedizin Rostock
    Rostock, Germany
    Recruiting
    • Ulrich Langenkamp, Dr. · Contact
  • DIAK Klinikum Schwäbisch Hall
    Schwäbisch Hall, Germany
    Recruiting
    • Thomas Geer, Dr. · Contact
  • Marienkrankenhaus Siegen
    Siegen, Germany
    Recruiting
    • Elisabeth Mack, Dr. · Contact
  • Klinikum Stuttgart
    Stuttgart, Germany
    Recruiting
    • Wolfram Bohle, Dr. · Contact
  • Marienhospital Stuttgart
    Stuttgart, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Krankenhaus der Barmherzigen Brüder Trier
    Trier, Germany
    Recruiting
    • Iordanis Deligiannis, Dr. · Contact
  • Universitätsklinikum Ulm
    Ulm, Germany
    Recruiting
    • Thomas J. Ettrich, Dr. · Contact
  • Klinikum Wetzlar
    Wetzlar, Germany
    Recruiting
    • Birgitta Killing, Dr. · Contact
  • Onkologisches Zentrum Wolfsburg-Helmstedt
    Wolfsburg, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Petrus-Krankenhaus Wuppertal
    Wuppertal, Germany
    Recruiting
    • Matthias Sandmann, Dr. · Contact
  • Gemeinschaftspraxis Würzburg
    Würzburg, Germany
    Recruiting
    • Björn Schöttker, Dr. · Contact
08

References and documents

Publications

  • Raschzok N, Stintzing S, Heinemann V, Rauch G, Ricke J, Guckenberger M, Kurreck A, Alig AHS, Stahler A, Bullinger L, Schmelzle M, Schoning W, Lurje G, Krenzien F, Haase O, Rau B, Gebauer B, Sauer IM, Pratschke J, Modest DP. FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. BMC Cancer. 2022 Apr 2;22(1):359. doi: 10.1186/s12885-022-09422-6. PubMed 35366831 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Nov 2027, 71 months after the start.

Of 106 non-industry phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 116. This study's planned 71 months is close to that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2021
First posted
Aug 17, 2021
StartActual
Dec 6, 2021
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2030
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05008809
Lead sponsor
Dominik Paul Modest
Collaborators
German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Responsible party
Dominik Paul Modest (Prof. Dr. med., Charite University, Berlin, Germany) — Sponsor-investigator
First posted
Aug 17, 2021
Start date
Dec 6, 2021
Primary completion
Nov 2027 (estimated)
Completion
Nov 2030 (estimated)
Last update
Dec 12, 2025

Study contacts

Dominik Modest, Prof. Dr.
Contact
dominik.modest@charite.de
+49 30 450 ext. 553222
Daniel Müller, Dr.
Contact
mueller.daniel@ikf-khnw.de
+49 69 7601 ext. 125
Dominik Modest, Prof. Dr.
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion